Background/purpose: A cutoff point in a test with sounded validity and professional preferences can help to make an accurate clinical decision. This study aimed to determine a cutoff point between two strategies for a developmental screening checklist (referred to as Taipei II). Cutoff point A was set as one or more item failed and cutoff point B was set as two or more items failed or one or more marked item failed.
Methods: This study was based on the total expected utilities of professional preferences and overall diagnostic indices. A self-administered questionnaire was developed to collect the estimated utility from professionals involved in early childhood interventions (n = 81) regarding four screening outcomes (probabilities of true positive, false positive, true negative, or false negative) and costs. The total expected utilities were calculated from the probabilities of four screening outcomes and utility values.
Results: The diagnostic odds ratio was higher for strategy B (695 and 209, respectively) than that of strategy A (184 and 150, respectively) when using the Taipei II on children under 3 years of age and age 3 and over. Strategy B also had a higher median total expected utilities score than strategy A (0.78 vs. 0.72 for children < 3 and 0.76 vs. 0.67 for children > or = 3).
Conclusion: If only one cutoff point can be chosen, the authors suggest that clinicians should choose cutoff point B when using the Taipei II for screening. However, two cutoff points of Taipei II, a combination of strategy A and B, can also be used clinically.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0929-6646(10)60044-7 | DOI Listing |
J Clin Oncol
January 2025
Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of China, Shatin, Hong Kong Special Administrative Region, China.
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.
View Article and Find Full Text PDFCodas
January 2025
Programa de Pós-graduação em Distúrbios da Comunicação Humana, Departamento de Fonoaudiologia, Universidade Federal de Santa Maria - UFSM - Santa Maria (RS), Brasil.
Purpose: To present the criterion validity, sensitivity, specificity, and cut-off scores for the Profiles of Early Expressive Phonological Skills Test - Brazilian Portuguese (PEEPS-BP) - Expanded List.
Methods: This was a quantitative cross-sectional psychometric study. The sample consisted of 30 children with no identified neurodevelopmental disorders aged 24 to 36 months.
Cad Saude Publica
January 2025
Universidade Estadual de Campinas, Campinas, Brasil.
This study aims to examine the prevalence of abdominal obesity-dynapenia phenotype, identified by the presence of abdominal obesity and dynapenia, and understand its associated factors with a representative sample of the Brazilian population. Data were collected from the baseline of the Brazilian Longitudinal Study of Aging (ELSI-Brasil) 2015-2016. Abdominal obesity was determined by a waist-to-height ratio ≥ 0.
View Article and Find Full Text PDFEur Radiol
January 2025
Department of Urological Surgical, JiangNan University Medical Center, Wuxi, China.
Objective: To conduct a meta-analysis assessing the diagnostic performance of the node reporting and data system (Node-RADS) for detecting lymph node (LN) invasion.
Method: We performed a systematic literature search of online scientific publication databases from inception up to July 31, 2024. We used the quality assessment of diagnostic accuracy studies-2 (QUADAS-2) to assess the study quality, and heterogeneity was determined by the Q-test and measured with I statistics.
J Clin Gastroenterol
January 2025
The Third Central Hospital of Tianjin, Hedong District.
Goals: To explore dynamic contrast-enhanced ultrasound (CEUS) parameters in predicting hepatic vein pressure gradient (HVPG) for patients with liver cirrhosis (LC).
Background: Noninvasive diagnosis of HVPG remains a challenge.
Study: This prospective study included patients with LC undergoing hepatic vein catheterization and pressure measurement at the hospital from May 2021 to January 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!